tbuckley/cabot-search huggingface dataset:
Use of a standardized web-based tool (WBT) for evaluation of aromatase inhibitor (AI) related bone loss in breast cancer patients (BCP)
Authors: G. D. Wong, K. Arnaoutakis, L. Martin, E. Blanchard, R. Parameswaran
Journal: Journal of Clinical Oncology (2008)

20754 Background: ASCO guidelines recommend AI adjuvant therapy in postmenopausal hormone receptor positive BCP. AI treated BCP have a higher rate of osteoporosis (OP); timely diagnosis and treatment can prevent fractures. WBT’s enable physicians to analyze practice data, develop improvement plans and comply with national guidelines. This study measures WBT use for OP diagnostic evaluation and oncology trainee (OT) education using the American Board Internal Medicine Practice Improvement Module (ABIM PIM) for OP. Methods: We performed a retrospective chart review (2004–06) of BCP on adjuvant AI without prior tamoxifen use; documentation of OP risk factors and processes of care was reviewed. OT knowledge was prospectively evaluated with two 6 monthly questionnaires (10 questions) extrapolated from the ABIM PIM. Results: Of 228 BCP identified from the hospital tumor registry, 28 (93% Caucasian, 7% race not documented) were eligible for analysis; mean age was 64 years (range 42–90). Post menopausal status was documented by history in 26 (92%); by LH, FSH and estradiol levels in 2 (8%) BCP. All tumors expressed estrogen receptors; 26 (92%) expressed progesterone receptors. Chart review revealed documentation of tobacco use in 19 (71%); exercise level in 12 (43%); fall screen in 1 (4%); vitamin D level in 0 (0%); appropriate vitamin D intake in 10 (36%) and calcium intake in 6 (21%) charts respectively. Bone density scan was done in 21 (75%) BCP. Of 17 (60%) BCP eligible for antiresorptive therapy; only 1 (6%) had documentation of prescribed therapy. Five OT answered the OP questionnaire evaluating risk factors. OT had a mean correct score of 54% at baseline; repeat mean correct score at 6 months was 66%. Conclusions: The ABIM PIM OP survey is a useful WBT in AI treated BCP. It identifies patients at high risk of OP, reveals deficiencies in chart documentation and provides an educational tool for physicians. By identifying high-risk patients in a timely fashion, management modifications can be made, potentially reducing OP related complications. We conclude that use of WBT in select patient populations enhances quality of patient care and can serve as an educational tool for oncology trainees. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration American Board of Internal Medicine
Non-Hodgkin’s Lymphoma After Primary Hodgkin’s Disease in the German Hodgkin’s Lymphoma Study Group: Incidence, Treatment, and Prognosis
Authors: Ulrich Rueffer, Andreas Josting, Jeremy Franklin, Michael May, Markus Sieber, Kai Breuer, Andreas Engert, Volker Diehl for the German Hodgkin’s Lymphoma Study Group
Journal: Journal of Clinical Oncology (2001)

The cumulative incidence for non-Hodgkin lymphoma's (NHL) after primary Hodgkin's disease (HD) ranges between 1% and 6%. To investigate the course of disease for secondary NHL, we retrospectively analyzed patients treated within clinical trials of the German Hodgkin's Lymphoma Study Group (GHSG) since 1981.From 1981 to 1998, the GHSG conducted three generations of clinical trials for the treatment of primary HD involving a total of 5,406 patients. Reference histology by an expert panel was obtained for 4,104 of the patients. Data on incidence, treatment, and outcome of secondary NHL were updated in March 1999.At first diagnosis of HD, the pathologists rejected 114 (2.1%) of 5,520 cases initially diagnosed as HD and rediagnosed them as primary NHL. Fifty-two (0.9%) of the remaining 5,406 patients developed a secondary NHL. One patient was excluded from further analyses because of insufficient documentation. Six patients had no further therapy because of patient refusal (n = 1) or rapidly progressive disease (n = 5). For the remaining 45 patients, overall response rate was 43% (36% complete response and 7% partial response). The actuarial 2-year freedom from treatment failure (FFTF) and overall survival (OS) for all patients was 24% and 30%, respectively, and for patients with diffuse large-cell lymphoma, it was 28% and 35%, respectively. Time of occurrence of secondary NHL after first diagnosis of HD and variables employed in the age-adjusted International Prognostic Factor Index (IPFI) significantly influenced treatment outcome.In the GHSG, the incidence of secondary NHL with 0.9% is relatively low compared with previously reported series. The prognosis of secondary NHL seems dismal and is significantly influenced by time of occurrence and the age-adjusted IPFI. In a subset of patients with secondary NHL, long-term disease-free survival could be achieved.
Cγ1 Deficiency Exacerbates Collagen‐Induced Arthritis
Authors: Richard T. Strait, Sherry Thornton, Fred D. Finkelman
Journal: Arthritis & Rheumatology (2016)

Objective IgG antibodies protect by aggregating pathogens and activating complement and stimulatory Fcγ receptors (FcγR). Although IgG1 accounts for a large percentage of murine serum antibodies, it poorly activates complement, binds more avidly to inhibitory FcγRIIb than to stimulatory FcγRIII, and has a relatively low aggregating ability. We previously demonstrated that IgG1 protects against complement‐ and FcγR‐independent renal disease by inhibiting immune complex obstruction of glomerular capillaries. The purpose of this study was to determine whether IgG1 also protects against the complement‐ and FcγR‐dependent disorder, collagen‐induced arthritis (CIA). Methods CIA was induced by injecting mice with type II collagen (CII) (active model) or with IgG2a and IgG2b anti‐CII monoclonal antibodies (ArthritoMab) (passive model). Arthritis severity was assessed, and CII‐specific IgG was titered. Results Cγ1‐deficient C57BL/6 mice lack IgG1 (IgG1 −/− ); in these mice, arthritis developed at a higher frequency and was more severe compared with IgG1 +/+ mice in the active model. Disease was FcγRIII‐ and C3‐dependent in both the IgG +/+ and IgG −/− mouse strains and was not influenced by interleukin‐4 receptor α in either strain. CII‐specific IgG2a/c titers were considerably higher in IgG1 −/− than in IgG1 +/+ mice and correlated with CIA incidence and severity. IgG1 +/+ mice that developed CIA had higher CII‐specific IgG1 and IgG2a/c levels than did those without CIA. CII‐inoculated BALB/c IgG1 +/+ and IgG1 −/− mice had much lower CII‐specific IgG2a/c titers than did C57BL/6 mice and failed to develop CIA but developed passive CIA when given ArthritoMab. Conclusion The absence of a functional Cγ1 gene indirectly promotes the development of CIA, likely through increased production of IgG2a/c, an isotype that strongly activates complement and stimulatory FcγR.
The role of 18F-FDG PET/CT for the diagnosis and follow-up of relapsing polychondritis
Authors: Jinlin Wang, Yunxiang Ceng, Chunli Liu, Nuofu Zhang, Shiyue Li
Journal: European Respiratory Journal (2013)

Background  RP is a rare autoimmune disorder which is associated with inflammation in cartilages,tissues throughout the body and much remains to be elucidated. PET/CT,as one of imaging techniques used to evaluate RP,have been previously reported in case reports.At present, PET/CT does not have a well-established role in the asseement of patients with RP, and future prospective studies are required to define the cost-effectiveness and clinical impact in this patient group more accurately.   Objectives  To investigate retrospectively the role of PET/CT for the diagnosis and follow-up of RP.   Methods  PET/CT findings were reviewed in six patients with RP.The initial PET/CT scans were performed 1 h and 2 h after FDG injection in all six patients. Follow- up PET/CT scans were performed during or followings teroid therapy in five patients.   Results  The initial PET/CT scans revealed intense FDG uptake by RP in all six patients.The maximum standardized uptake value increased in six patients. The lesions of abnormal FDG uptake were: tracheal/bronchial cartilage (n=6), costicartilage(n=4),nasal cartilage(n=4), cricoid cartilage(n=4),arytenoid cartilage (n=3),thyroid cartilage(n=3), auricular cartilage (n=3). The intense uptake in the cartilage reduced or disappeared during or following steroid therapy in five patients.   Conclusions  PET/CT enables the acquisition of all the carilages images and provides function information ,it has valuable role in assessing all the carilages and detecting RP,guiding the selection of a biopsy site and monitoring respone to treatment.
Role of dose intensity of TLR9 agonist CpG ODN (CPG 7909) in the treatment of metastatic murine renal cell carcinoma
Authors: H. L. Davis, R. D. Weeratna, L. L. Bourne, S. M. Sullivan, M. J. McCluskie, A. M. Krieg
Journal: Journal of Clinical Oncology (2004)

3182 Background: Synthetic oligodeoxynucleotides containing CpG motifs (CpG ODN) directly activate the innate immune system by stimulating B cells to proliferate and secrete immunoglobulin, IL-6 and IL-10; NK cells to produce IFN-γ; and monocytes and dendritic cells to produce IL-6, IL-12, IL-18, TNF-α and IFN-α. CpG ODN can also activate the adaptive immune system when presented with an antigen. Thus, CpG ODN appear to be a potent immune activator that would be desirable for cancer immunotherapy. Herein, we examine the potential of CpG ODN to enhance the survival of mice with advanced metastatic murine renal cell carcinoma (Renca). Methods: BALB/c mice were injected with 1 x 105 Renca cells under the left kidney capsule. Animals were treated with CPG 7909 beginning on day 5 after tumor inoculation, and administered either as: (1) a single injection of 200 μg; (2) 4 injections of 50 μg administered at 4 distant sites weekly (3) two 100 μg injections given biweekly; or (4) 40 μg s. c. injections given daily for five consecutive days each week. All treatments lasted from day 5 to 58 post tumor induction. Results: Median survival improved from 28 days to 34 days for group 1, treated once with 200 μg CPG 7909, to 33 days for group 3 treated twice weekly with 100 μg each time and 31 days for group 4 treated on five consecutive days with 40 μg each time. The group treated once weekly with 4 injections of 50 μg each administered at 4 distant sites of the body had 80% of the animals surviving on day 35 post tumor induction. Conclusions: CPG 7909 is thus effective in prolonging survival in this metastatic Renca model, and more intense administration schedules provided the best efficacy of treatment. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Coley Pharmaceutical Group Coley Pharmaceutical Group Coley Pharmaceutical Group
Abstract 14205: Myocardial Injury Induces AIM2 Inflammasome Expression in Neutrophil Granulocytes in Patients With Acute Myocardial Infarction
Authors: Jedrzej Hoffmann, Lukas Pyttel, Peter Thiele, Christian Troidl, Christoph Liebetrau, Sebastian Szardien, Matthias Willmer, Sandra Voss, Christian Hamm, Holger Nef, Helge Mollmann
Journal: Circulation (2013)

Background: Neutrophils (PMN) are primed and recruited to sites of sterile inflammation, including myocardial tissue injury following acute myocardial infarction (AMI). It has been shown that speci...
Abstract 11319: Smoking and Smoking Cessation in Relation to All-cause Mortality, Stroke, Ischemic Heart Disease, and Total Cardiovascular Events in Young- and Middle-aged Japanese Men
Authors: Takahisa Kondo, Shigeki Osugi, Keiko Shimokata, Haruo Honjo, Yasuhiro Morita, Kengo Maeda, Kentaro Yamashita, Takashi Muramatsu, Satoshi Shintani, Kunihiro Matsushita, Toyoaki Murohara
Journal: Circulation (2010)

Background Data regarding associations among smoking, smoking cessation, mortality, and cardiovascular disease (CVD) is still inadequate in young- and middle-aged Asians. Methods and Results A tota...
Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma
Authors: Jessica N Cooke Bailey, Stephanie J Loomis, Jae H Kang, R Rand Allingham, Puya Gharahkhani, Chiea Chuen Khor, Kathryn P Burdon, Hugues Aschard, Daniel I Chasman, Robert P Igo, Pirro G Hysi, Craig A Glastonbury, Allison Ashley-Koch, Murray Brilliant, Andrew A Brown, Donald L Budenz, Alfonso Buil, Ching-Yu Cheng, Hyon Choi, William G Christen, Gary Curhan, Immaculata De Vivo, John H Fingert, Paul J Foster, Charles Fuchs, Douglas Gaasterland, Terry Gaasterland, Alex W Hewitt, Frank Hu, David J Hunter, Anthony P Khawaja, Richard K Lee, Zheng Li, Paul R Lichter, David A Mackey, Peter McGuffin, Paul Mitchell, Sayoko E Moroi, Shamira A Perera, Keating W Pepper, Qibin Qi, Tony Realini, Julia E Richards, Paul M Ridker, Eric Rimm, Robert Ritch, Marylyn Ritchie, Joel S Schuman, William K Scott, Kuldev Singh, Arthur J Sit, Yeunjoo E Song, Rulla M Tamimi, Fotis Topouzis, Ananth C Viswanathan, Shefali Setia Verma, Douglas Vollrath, Jie Jin Wang, Nicole Weisschuh, Bernd Wissinger, Gadi Wollstein, Tien Y Wong, Brian L Yaspan, Donald J Zack, Kang Zhang, EPIC-Norfolk Eye Study, Robert N Weinreb, Margaret A Pericak-Vance, Kerrin Small, Christopher J Hammond, Tin Aung, Yutao Liu, Eranga N Vithana, Stuart MacGregor, Jamie E Craig, Peter Kraft, Gareth Howell, Michael A Hauser, Louis R Pasquale, Jonathan L Haines, Janey L Wiggs
Journal: Nature Genetics (2016)
A new academic faculty evaluation tool using graphic representation of clinical, research, teaching and administration domains
Authors: D. R. Spriggs
Journal: Journal of Clinical Oncology (2005)

6095 Background: Academic oncologists have multiple tasks for which they are responsible including clinical activity, academic activities (grants and publications), teaching responsibilities and administrative activities, both local and national. The quantitative evaluation of individuals across multiple performance domains is a complicated process which often leaves the faculty and leadership frustrated and confused about competing expectations and inconsistent evaluations. Methods: As part of the biannual reappointment process, we collected data of 65 members of the Division of Solid Tumor Oncology in a variety of areas including outpatient activity, inpatient activity, chemotherapy encounters, publications, grants and contracts, protocol leadership and accrual, teaching evaluation, didactic teaching hours, local conference attendance and administrative activities (local and national). The data was collated, ranked and presented as quartile performance in each of these areas, using a 4 quadrant normalized graphic to visually present a profile of activity across all four academic domains. Results: In this analysis, it is possible to present performance data for a faculty member in a compact, visual graphic which allows simultaneous presentation of all four academic domains. By scaling against either local peer performance or external standards, it is possible to provide either relative or absolute performance appraisals. The concise nature of the presentation format also allows sequential progress evaluation over time, comparison to peers at the similar rank, and identification of individual strengths and weaknesses across the domains. Conclusions: This graphic represents an integrated visual tool for the analysis and evaluation of academic performance across clinical care, teaching, research and administration. Validation of the tool is required against historical qualitative analysis across several institutions but may ultimately provide a less biased method for evaluation of diversely skilled faculty members during reappointment and promotion in academic settings. No significant financial relationships to disclose.
Abstract 3805: Effect of Imatinib mesylate in gastric cancer cell progression
Authors: Jung Lim Kim, Bo Ram Kim, Yoo Jin Na, Seong Hye Park, Yoon A Jeong, Sang Cheul Oh
Journal: Cancer Research (2015)

Abstract Imatinib is a powerful tyrosine kinase inhibitor that specifically targets BCR-ABL, KIT, and PDGFR kinases that is used in the treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GIST), and other cancers. But, imatinib mesylate has not yet been reported about anti-cancer effect in gastric cancer. This study was undertaken to evaluate the in vitro effect of imatinib mesylate in gastric cancer cells and to define molecular mechanism underlying these effects. This study was to determine the expression of PDGFR molecules in gastric cancer cells (AGS, MKN28, MKN45, SNU638) by semi-quantitative polimerase chain reaction (PCR). The effects of imatinib mesylate on gastric cancer cells were examined in four human gastric cancer cell lines. The results showed expression of PDGFR in all four gastric cancer cells. We measured the sensitivity of gastric cancer cell line (AGS, MKN28, MKN45, SNU638) to imatinib mesylate using MTT assay. Cell viability of cell treated with imatinib mesylate was decreased in high dose. But cell viability was not change in high dose. Next, the results showed expression of PDGFR and suppression of its phosphorylation by imatinib mesylate in all four gastric cancer cells. Cell cycle analysis for sub-G1 and G2/M fraction also detected the increased cell death in the cells treated with imatinib mesylates. Results by Western blotting indicated that imatinib mesylates promotes apoptosis of gastric cancer cells by both activating caspase-3 and -9 and inducing PARP cleavage. And expression of p-AKT level was decreased. Cell migration and invasion that imatinib treated cells is decreased in low dose. Cell viability assay revealed that the combination of imatinib mesylate and chemo-reagent synergistically inhibited cell growth compared to cells treated with any of the agent alone. In conclusion, inhibition the PDGFR by imatinib mesylates lead to apoptosis of gastric cancer cell lines. And Imatinib suppressed motility and invasion of gastric cancer cells. The results suggest that imatinib mesylate may be useful in the treatment of gastric cancer. Note: This abstract was not presented at the meeting. Citation Format: Jung Lim Kim, Bo Ram Kim, Yoo Jin Na, Seong Hye Park, Yoon A Jeong, Sang Cheul Oh. Effect of Imatinib mesylate in gastric cancer cell progression. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3805. doi:10.1158/1538-7445.AM2015-3805
Abstract 18673: Human Enzyme Replacement Therapy in a Patient With Familial Lecithin Cholesterol Acyltransferase Deficiency: Rapid Appearance of Normal Appearing HDL
Authors: Robert D Shamburek, Lita Freeman, Maureen Sampson, Rebecca Bakker-Arkema, Brian Krause, Bruce Auerbach, Ryan Homan, Alexandra Shamburek, Charles Schwartz, Marcelo Amar, Alan Remaley
Journal: Circulation (2013)

Introduction: Lecithin cholesterol acyltransferase (LCAT) is a liver-derived enzyme in plasma that catalyzes the formation of cholesteryl esters (CE). Mutations in the human LCAT gene result in familial LCAT deficiency (FLD), characterized by absent high-density lipoprotein cholesterol (HDL-C), corneal opacities, anemia, and severe renal disease. Replacing the defective enzyme should restore the normal level of plasma CE (LCAT product) and lead to the appearance of alpha HDL (α-HDL) lipoproteins. Aim: To assess the formation of CE and the appearance of HDL over time in a FLD patient with recombinant human LCAT (ACP-501). Methods: A FLD subject with very low HDL-C (&lt;5 mg/dL), corneal opacities, stage 4/5 renal disease, anemia, and splenomegaly received a 1 hour infusion of recombinant human LCAT (rhLCAT) and serial plasma samples were collected over 7 days. Results: HDL-C increased from &lt;5 mg/dL to 17 mg/dL at 8 hours and remained measurable for 7 days. CE increased rapidly, doubling in concentration within 2 hours, and sustained a higher concentration than HDL over 7 days. An increase in LDL-C was delayed about 6 hours suggesting CETP transfer of CE from HDL to LDL. Small sized particles were rapidly converted to HDL2 and HDL3 sized particles on FPLC. Large α-HDL appeared on agarose electrophoresis within 30 minutes. ApoAI Western blot analysis confirmed the rapid generation of apoAI staining α-HDL. α-1, 2 and 3 particles rapidly appeared by 2-D gel electrophoresis. Filipin stained 1-D gels revealed large α particles that persisted for 7 days. α-4 sized particles decreased as α-HDL formed. Sudan stained 1-D gels showed the generation of CE-rich α-HDL. Conclusions: The infusion of rhLCAT (ACP-501) in a lecithin cholesterol acyltransferase deficient subject with no HDL rapidly generated CE and α-HDL with evidence of sustained activity over 7 days. CE appeared in LDL suggesting the transfer of CE from HDL to LDL by CETP. The lipid and lipoprotein changes are consistent with normal HDL maturation.
A randomized trial of 6-minutes drip infusion versus 1-minute bolus injection of vinorelbine (VNR) for the control of drug induced-phlebitis
Authors: K. Yoh, S. Niho, K. Goto, H. Ohmatsu, K. Kubota, R. Kakinuma, Y. Nishiwaki
Journal: Journal of Clinical Oncology (2004)

8117 Background: VNR is most commonly administered through a peripheral vein over a period of between 6 to 10 minutes. However administration of VNR may result in development of a chemical phlebitis or venous irritation. It is reported that the incidence of VNR induced-phlebitis may decrease with shortening the infusion time. We conducted a prospective randomized trial comparing 1-minute bolus injection with 6-minutes drip infusion of VNR. Methods: VNR-naïve patients with lung cancer receiving VNR-containing chemotherapy as peripheral infusion were randomized to receive either 6-minutes drip infusion (arm A) or 1-minute bolus injection (arm B) of VNR. VNR was diluted in 50 ml (arm A) or 20 ml (arm B) normal saline, respectively. A phlebitis and/or venous irritation were evaluated after each cycle and graded according to the NCI-CTC version 2.0 for injection site reaction. Results: Eighty-three patients were enrolled into the study and 81 of them assessable for analysis. One hundred thirty-eight cycles to 40 patients with arm A and 135 cycles to 41 patients with arm B had been delivered. A phlebitis and/or venous irritation were observed in 33% of patients in arm A and 24% in arm B. There was no statistically significant difference between two arms (P=0.41). No severe phlebitis and/or venous irritation were seen with arm A or B. Conclusions: Administration with 1-minute bolus injection of VNR does not appear to significantly decrease the incidence of drug-induced phlebitis compared with 6-minutes drip infusion. No significant financial relationships to disclose.
Legal Battles Over Embryos After In Vitro Fertilization
Authors: Clarisa R. Gracia, Susan L. Crockin
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal